Metastatic Malignant Transformation of Teratoma to Primitive Neuroectodermal Tumor (PNET): Results with PNET-based Chemotherapy

Ahmad A. Al-Hader, Amit Jain, Nawar Al-Nasrallah, Lawrence Einhorn

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Metastatic germ cell cancers are highly chemosensitive and have 80% cure rate with cisplatin-based chemotherapy. Postchemotherapy teratoma can usually be surgically resected. However, teratoma, which is pluripotent tissue, can undergo malignant transformation along mesodermal elements to primitive neuroectodermal tumor (PNET). Unlike teratoma, PNET can metastasize and render a patient unresectable and incurable. We report the results of treatment of patients with malignant transformation to PNET with cyclophosphamide+doxorubicin+vincristine (CAV) alternating with ifosfamide+etoposide (IE). Methods: We reviewed 86 patients with histologically confirmed PNET transformed from testicular teratoma at Indiana University from 1998 to 2012. We identified 18 patients who were treated with chemotherapy comprising cyclophosphamide (1000 to 1200 mg/m 2), doxorubicin (50 to 75 mg/m 2), and vincristine (2 mg) alternating with ifosfamide (1.8 g/m 2) plus etoposide (100 mg/m 2) for 5 consecutive days. Treatment was given every 3 weeks with a maximum of 6 cycles or until progression or undue toxicity. Hematopoietic growth factors were usually incorporated. The remaining 68 patients underwent surgical resection. Results: Twelve patients had unresectable disease and 6 were treated in an adjuvant setting. Median age was 29 years (range, 20 to 53 y). Nine of the 12 metastatic patients achieved objective response by RECIST criteria. Six of those were rendered with no evidence of disease (NED) with further surgery. Although 4 of the 6 patients subsequently relapsed, 1 patient remains alive and NED at 78 months. The 6 patients who received adjuvant treatment are alive with NED at 9 to 90 months with a median duration of 32.7 months. Conclusions: CAV and IE alternating chemotherapy has high objective response rate for PNET transformed from teratoma and results in occasional long-term disease-free survival when combined with subsequent resection. We recommend adjuvant CAV alternating with IE chemotherapy for patients with PNET after RPLND due to the high probability of recurrent disease and their high chemosensitivity to this regimen.

Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number4
DOIs
StatePublished - Aug 6 2015

Fingerprint

Primitive Neuroectodermal Tumors
Teratoma
Drug Therapy
Ifosfamide
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Germ Cell and Embryonal Neoplasms
Cisplatin
Disease-Free Survival
Intercellular Signaling Peptides and Proteins
Therapeutics

Keywords

  • cyclophosphamide/doxorubicin/vincristine (CAV)
  • ifosfamide/etoposide (IE)
  • primitive neuroectodermal tumor (PNET)
  • teratoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Metastatic Malignant Transformation of Teratoma to Primitive Neuroectodermal Tumor (PNET) : Results with PNET-based Chemotherapy. / Al-Hader, Ahmad A.; Jain, Amit; Al-Nasrallah, Nawar; Einhorn, Lawrence.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 38, No. 4, 06.08.2015, p. 364-366.

Research output: Contribution to journalArticle

@article{8c5ee63116ca4054be5d0f25e157f9d2,
title = "Metastatic Malignant Transformation of Teratoma to Primitive Neuroectodermal Tumor (PNET): Results with PNET-based Chemotherapy",
abstract = "Background: Metastatic germ cell cancers are highly chemosensitive and have 80{\%} cure rate with cisplatin-based chemotherapy. Postchemotherapy teratoma can usually be surgically resected. However, teratoma, which is pluripotent tissue, can undergo malignant transformation along mesodermal elements to primitive neuroectodermal tumor (PNET). Unlike teratoma, PNET can metastasize and render a patient unresectable and incurable. We report the results of treatment of patients with malignant transformation to PNET with cyclophosphamide+doxorubicin+vincristine (CAV) alternating with ifosfamide+etoposide (IE). Methods: We reviewed 86 patients with histologically confirmed PNET transformed from testicular teratoma at Indiana University from 1998 to 2012. We identified 18 patients who were treated with chemotherapy comprising cyclophosphamide (1000 to 1200 mg/m 2), doxorubicin (50 to 75 mg/m 2), and vincristine (2 mg) alternating with ifosfamide (1.8 g/m 2) plus etoposide (100 mg/m 2) for 5 consecutive days. Treatment was given every 3 weeks with a maximum of 6 cycles or until progression or undue toxicity. Hematopoietic growth factors were usually incorporated. The remaining 68 patients underwent surgical resection. Results: Twelve patients had unresectable disease and 6 were treated in an adjuvant setting. Median age was 29 years (range, 20 to 53 y). Nine of the 12 metastatic patients achieved objective response by RECIST criteria. Six of those were rendered with no evidence of disease (NED) with further surgery. Although 4 of the 6 patients subsequently relapsed, 1 patient remains alive and NED at 78 months. The 6 patients who received adjuvant treatment are alive with NED at 9 to 90 months with a median duration of 32.7 months. Conclusions: CAV and IE alternating chemotherapy has high objective response rate for PNET transformed from teratoma and results in occasional long-term disease-free survival when combined with subsequent resection. We recommend adjuvant CAV alternating with IE chemotherapy for patients with PNET after RPLND due to the high probability of recurrent disease and their high chemosensitivity to this regimen.",
keywords = "cyclophosphamide/doxorubicin/vincristine (CAV), ifosfamide/etoposide (IE), primitive neuroectodermal tumor (PNET), teratoma",
author = "Al-Hader, {Ahmad A.} and Amit Jain and Nawar Al-Nasrallah and Lawrence Einhorn",
year = "2015",
month = "8",
day = "6",
doi = "10.1097/COC.0b013e31829d1ed7",
language = "English (US)",
volume = "38",
pages = "364--366",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Metastatic Malignant Transformation of Teratoma to Primitive Neuroectodermal Tumor (PNET)

T2 - Results with PNET-based Chemotherapy

AU - Al-Hader, Ahmad A.

AU - Jain, Amit

AU - Al-Nasrallah, Nawar

AU - Einhorn, Lawrence

PY - 2015/8/6

Y1 - 2015/8/6

N2 - Background: Metastatic germ cell cancers are highly chemosensitive and have 80% cure rate with cisplatin-based chemotherapy. Postchemotherapy teratoma can usually be surgically resected. However, teratoma, which is pluripotent tissue, can undergo malignant transformation along mesodermal elements to primitive neuroectodermal tumor (PNET). Unlike teratoma, PNET can metastasize and render a patient unresectable and incurable. We report the results of treatment of patients with malignant transformation to PNET with cyclophosphamide+doxorubicin+vincristine (CAV) alternating with ifosfamide+etoposide (IE). Methods: We reviewed 86 patients with histologically confirmed PNET transformed from testicular teratoma at Indiana University from 1998 to 2012. We identified 18 patients who were treated with chemotherapy comprising cyclophosphamide (1000 to 1200 mg/m 2), doxorubicin (50 to 75 mg/m 2), and vincristine (2 mg) alternating with ifosfamide (1.8 g/m 2) plus etoposide (100 mg/m 2) for 5 consecutive days. Treatment was given every 3 weeks with a maximum of 6 cycles or until progression or undue toxicity. Hematopoietic growth factors were usually incorporated. The remaining 68 patients underwent surgical resection. Results: Twelve patients had unresectable disease and 6 were treated in an adjuvant setting. Median age was 29 years (range, 20 to 53 y). Nine of the 12 metastatic patients achieved objective response by RECIST criteria. Six of those were rendered with no evidence of disease (NED) with further surgery. Although 4 of the 6 patients subsequently relapsed, 1 patient remains alive and NED at 78 months. The 6 patients who received adjuvant treatment are alive with NED at 9 to 90 months with a median duration of 32.7 months. Conclusions: CAV and IE alternating chemotherapy has high objective response rate for PNET transformed from teratoma and results in occasional long-term disease-free survival when combined with subsequent resection. We recommend adjuvant CAV alternating with IE chemotherapy for patients with PNET after RPLND due to the high probability of recurrent disease and their high chemosensitivity to this regimen.

AB - Background: Metastatic germ cell cancers are highly chemosensitive and have 80% cure rate with cisplatin-based chemotherapy. Postchemotherapy teratoma can usually be surgically resected. However, teratoma, which is pluripotent tissue, can undergo malignant transformation along mesodermal elements to primitive neuroectodermal tumor (PNET). Unlike teratoma, PNET can metastasize and render a patient unresectable and incurable. We report the results of treatment of patients with malignant transformation to PNET with cyclophosphamide+doxorubicin+vincristine (CAV) alternating with ifosfamide+etoposide (IE). Methods: We reviewed 86 patients with histologically confirmed PNET transformed from testicular teratoma at Indiana University from 1998 to 2012. We identified 18 patients who were treated with chemotherapy comprising cyclophosphamide (1000 to 1200 mg/m 2), doxorubicin (50 to 75 mg/m 2), and vincristine (2 mg) alternating with ifosfamide (1.8 g/m 2) plus etoposide (100 mg/m 2) for 5 consecutive days. Treatment was given every 3 weeks with a maximum of 6 cycles or until progression or undue toxicity. Hematopoietic growth factors were usually incorporated. The remaining 68 patients underwent surgical resection. Results: Twelve patients had unresectable disease and 6 were treated in an adjuvant setting. Median age was 29 years (range, 20 to 53 y). Nine of the 12 metastatic patients achieved objective response by RECIST criteria. Six of those were rendered with no evidence of disease (NED) with further surgery. Although 4 of the 6 patients subsequently relapsed, 1 patient remains alive and NED at 78 months. The 6 patients who received adjuvant treatment are alive with NED at 9 to 90 months with a median duration of 32.7 months. Conclusions: CAV and IE alternating chemotherapy has high objective response rate for PNET transformed from teratoma and results in occasional long-term disease-free survival when combined with subsequent resection. We recommend adjuvant CAV alternating with IE chemotherapy for patients with PNET after RPLND due to the high probability of recurrent disease and their high chemosensitivity to this regimen.

KW - cyclophosphamide/doxorubicin/vincristine (CAV)

KW - ifosfamide/etoposide (IE)

KW - primitive neuroectodermal tumor (PNET)

KW - teratoma

UR - http://www.scopus.com/inward/record.url?scp=84938743169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938743169&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31829d1ed7

DO - 10.1097/COC.0b013e31829d1ed7

M3 - Article

C2 - 23799289

AN - SCOPUS:84938743169

VL - 38

SP - 364

EP - 366

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -